Bocsi J, Perner F, Szücs J, Glaz E, Kopper L
Ist Institute Pathology and Experimental Cancer Research, Semmelweis University of Medicine, Budapest, Hungary.
Anticancer Res. 1998 Jul-Aug;18(4B):2901-4.
The significance of DNA ploidy in indicating the benign or malignant character of parathyroid and other endocrin tumors is controversial.
DNA content of paraffin embedded parathyroid samples from 25 patients was measured with flow cytometry.
The DNA index (DI) was 1.0 in all nonneoplastic samples as well as in 50% of adenomas (10/20) and in one carcinoma (1/2). The remaining 45% of the adenoma cases (9/20) and the other carcinoma showed doubled DNA content (DI = 1.9-2.0). The increased DI did not correlate with either clinical data (sex, age, tumor size, preoperative serum Ca++ or parathormone, primary or secondary hyperparathyroidism) or morphology.
These results indicate that the DI has no value in deciding the benign or malignant character of a given sample. However, the prognostic value of tetraploidization (the potentially increased risk for malignancy) could not be ruled out.
DNA倍性在指示甲状旁腺及其他内分泌肿瘤的良恶性方面的意义存在争议。
采用流式细胞术测量25例患者石蜡包埋甲状旁腺样本的DNA含量。
所有非肿瘤性样本以及50%的腺瘤（20例中的10例）和1例癌（2例中的1例）的DNA指数（DI）为1.0。其余45%的腺瘤病例（20例中的9例）和另一例癌显示DNA含量加倍（DI = 1.9 - 2.0）。DI升高与临床数据（性别、年龄、肿瘤大小、术前血清Ca++或甲状旁腺激素、原发性或继发性甲状旁腺功能亢进）及形态学均无相关性。
这些结果表明DI在判定给定样本的良恶性方面无价值。然而，不能排除四倍体化的预后价值（潜在的恶性风险增加）。
